Trial · NCT06353282
MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents
NCT06353282, Phase 2, Withdrawn, University of California, Los Angeles
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents. Trials, record NCT06353282. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06353282
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents
- NCT number
- NCT06353282
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- University of California, Los Angeles
- Conditions
- PTSD, Post Traumatic Stress Disorder, Adolescents, Psychotherapy
- Interventions
- MDMA, Psychotherapy
- First posted
- 2024-04-09
- Last updated
- 2025-04-10
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in heart rhythm via Carnation Ambulatory Heart Monitor | Throughout the 24 hours prior to each experimental medication session, throughout the duration of each drug administration session, and the 24 hours following each experimental medication session. Up to 64 hours. | Changes in heart rhythm via Carnation Ambulatory Heart Monitor |
| Primary | Changes in blood pressure | Baseline assessment and at 1-hour intervals throughout each experimental medication session. Up to 17 hours total. | changes in blood pressure as measured by blood pressure machine |
| Primary | Change in pulse | Baseline assessment and at 1-hour intervals throughout each experimental medication session. Up to 17 hours total. | Change in pulse as part of measuring vitals |
| Primary | Change in body temperature | Baseline assessment and at 1-hour intervals throughout each experimental medication session. Up to 17 hours total | Changes in body temperature as measured by thermometer |
| Primary | Mean change in score of visual analog scale to assess potential for misuse of MDMA | Weekly throughout treatment and at 3-month and 6-month follow-ups. Through study completion, an average of 9 months | Investigate MDMA drug abuse potential through visual analog scale. Range for scale is 1-5 and will ask about the likability of the substance and the desire to use it in a non-clinical context. |
| Secondary | Mean change in PTSD symptom severity via the Child PTSD Symptom Scale | Baseline, One month Post Experimental Session, and 3 and 6 months post-treatment. Through study completion, an average of 9 months | Change in PTSD symptom severity via the Child PTSD Symptom Scale (CPSS). The Child PTSD Symptom Scale (CPSS) measures posttraumatic stress disorder diagnosis and severity in the past month in children aged 8 to 18. Possible scores range from 0 to 80, with higher scores indicating a worse outcome/greater severity of symptoms. |
| Secondary | Mean change in PTSD symptom severity via the Clinician-Administered PTSD Scale (CAPS-CA-5) | Baseline, One month Post Experimental Session, and 3 and 6 months post-treatment. Through study completion, an average of 9 months | Change in PTSD symptom severity via the CAPS-CA-5. The Clinician-Administered PTSD Scale(CAPS-CA-5) measures posttraumatic stress disorder symptoms in the past month in children aged 7 and above. Possible scores range from 0 to 80 , with higher scores indicating more severe PTSD symptoms. |
| Secondary | Mean change in depression symptom severity via the Patient Health Questionnaire-9 (PHQ-9). | Baseline and at each study visit following MDMA experimental medication sessions. Through study completion, an average of 9 months | Change in depressive symptom severity via the PHQ-9. The Patient Health Questionnaire-9 (PHQ-9) measures the severity of depression. Possible scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms. |
| Secondary | Mean change in anxiety symptom severity via the Generalized Anxiety Disorder 7-item (GAD-7) | Baseline and at each study visit following the experimental medication sessions. Through study completion, an average of 9 months | Change in Anxiety symptoms assessed by the GAD-7. Generalized Anxiety Disorder 7-item scale measures the severity of anxiety. Possible scores range from 0 to 21, with higher scores indicating greater anxiety severity. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06353282
GET https://conductscience.org/api/trials/v1/NCT06353282/registered